Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 14/20 | 0.43 |
| ▸ | MTNR1B | P49286 | 13/20 | 0.43 |
| ▸ | CA12 | O43570 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | CA7 | P43166 | 1/20 | 0.37 |
| ▸ | CA9 | Q16790 | 1/20 | 0.37 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.37 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.35 |
| ▸ | NQO2 | P16083 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21497100 | 0.86 | CA12 (0.36) | MTNR1AMTNR1BCA12CA1CA2 | |
| SCHEMBL27268842 | 0.85 | CA9 (0.41) | CA12CA1CA2CA7CA9 | |
| SCHEMBL21503787 | 0.85 | CA2 (0.41) | CA12CA1CA2CA7CA9 | |
| SCHEMBL21497094 | 0.85 | CA2 (0.41) | CA12CA1CA2CA7CA9 | |
| SCHEMBL21497086 | 0.85 | CA2 (0.41) | CA12CA1CA2CA7CA9 | |
| SCHEMBL21497099 | 0.84 | CA12 (0.40) | CA12CA1CA2CA7CA9 | |
| SCHEMBL21497091 | 0.84 | CA1 (0.40) | CA12CA1CA2CA7CA9 | |
| SCHEMBL21497098 | 0.83 | CA2 (0.39) | CA12CA1CA2CA7CA9 | |
| SCHEMBL27270456 | 0.83 | CA2 (0.39) | CA12CA1CA2CA7CA9 | |
| SCHEMBL21497095 | 0.79 | CA12 (0.35) | CA12CA1CA2CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12016868-B2 | Boronic acid derivatives and therapeutic uses thereof | QPEX BIOPHARMA, INC. (US) | 2024-06-25 | — | — | US | disclosed |
| US-12016868-B2 | Boronic acid derivatives and therapeutic uses thereof | QPEX BIOPHARMA, INC. (US) | 2024-06-25 | — | — | US | disclosed |
| EP-3781576-B1 | BORONIC ACID DERIVATIVES AND THERAPEUTIC USES THEREOF | QPEX BIOPHARMA INC (US) | 2024-06-12 | — | — | EP | disclosed |
| US-20210361682-A1 | BORONIC ACID DERIVATIVES AND THERAPEUTIC USES THEREOF | QPEX BIOPHARMA, INC. | 2021-11-25 | — | — | US | disclosed |
| EP-3781576-A1 | BORONIC ACID DERIVATIVES AND THERAPEUTIC USES THEREOF | QPEX BIOPHARMA, INC. (US) | 2021-02-24 | — | — | EP | disclosed |
| WO-2019204419-A1 | BORONIC ACID DERIVATIVES AND THERAPEUTIC USES THEREOF | THE MEDICINES COMPANY (SAN DIEGO), LLC (US) | 2019-10-24 | — | — | WO | disclosed |
| WO-2019204419-A1 | BORONIC ACID DERIVATIVES AND THERAPEUTIC USES THEREOF | THE MEDICINES COMPANY (SAN DIEGO), LLC (US) | 2019-10-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12016868-B2 | Boronic acid derivatives and therapeutic uses thereof | BCL6B, BCL6, BTD | MTNR1A 1916/4885MTNR1B 1124/4885CA12 220/4885 |
| US-20210361682-A1 | BORONIC ACID DERIVATIVES AND THERAPEUTIC USES THEREOF | BCL6B, BCL6, BTD | MTNR1A 1916/4885MTNR1B 1124/4885CA12 220/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.